Stella Diagnostics Inc.
SLDX · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 1.31 | 1.20 | 0.00 |
| FCF Yield | -1.97% | 3.69% | -0.32% | -0.21% |
| EV / EBITDA | -37.34 | -103.87 | -99.18 | -70.20 |
| Quality | ||||
| ROIC | 4.95% | 2.69% | 1.57% | 2.45% |
| Gross Margin | -62.20% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.49 | -2.77 | 0.19 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 585,931.01% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -149.57% | 1,294.91% | -25.77% | 92.92% |
| Safety | ||||
| Net Debt / EBITDA | -11.28 | -28.84 | -28.04 | -17.07 |
| Interest Coverage | -20.00 | 0.00 | -4.31 | -8.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -157.91 | 0.00 | 0.00 | 0.00 |